The Latest Cardiac and Vascular News
Risk Reductions of 46% to 52% for Heart Failure Readmissions and for Composite of CV Death and Heart Failure Readmissions at 30 and 90 Days Following Hospital Discharge THE WOODLANDS, Texas, Nov. 06, 2022 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that a new analysis of results from the […]
Forcefield Therapeutics presents positive preclinical data at the 2022 Scientific Sessions of American Heart Association Preclinical data outlining the mechanisms of three proteins shown to restore heart function following acute myocardial infarction (heart attack) presented at AHA Proteins were identified by FunSel technology and developed by Forcefield London UK, 7 November 2022 – Forcefield Therapeutics (“Forcefield”) Ltd, a pioneer of best-in-class therapeutics to protect […]
Data presented in late-breaking oral presentation demonstrated deep and consistent TTR reduction following a single dose of NTLA-2001 in patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM) Greater than 90% mean serum TTR reductions after a single dose of NTLA-2001 were sustained at both doses tested, with follow-up now reaching four […]
WALTHAM, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) — CinCor Pharma, Inc. (“CinCor”) announced the appointment of Michael W. Kalb as Executive Vice President and Chief Financial Officer (CFO), effective November 4. An accomplished financial executive with product launch and commercialization experience in cardiovascular therapeutics, Mr. Kalb brings over 25 years […]
WOODCLIFF LAKE, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) — Eagle Pharmaceuticals, Inc. is re-issuing in its entirety its earnings press release for the third quarter ended September 30, 2022, originally issued on November 7, 2022 at 6:50 am ET, to correct errors in the presentation of certain line items in the […]
VERVE-101 Investigational New Drug Application Placed on Hold by U.S. Food and Drug Administration Dosing Completed in First Dose Cohort of the heart-1 Clinical Trial of VERVE-101 in Patients with HeFH; Independent Data Safety Monitoring Board Recommended Proceeding to Second Dose Level in New Zealand and U.K. Well-capitalized with $550.7 […]
Late-breaking Data Demonstrate AHA/ACC Guideline-directed CCTA ± FFRCT Precision Pathway is Superior to Traditional Testing Using coronary computed tomography angiography (CCTA) with HeartFlow’s FFRCT Analysis to evaluate suspected coronary artery disease (CAD) offers more accurate non-invasive diagnosis, fewer unnecessary tests, and higher confidence in identifying patients needing treatment MOUNTAIN VIEW, […]
– Assessment showed participants who received a single dose of SLN360 maintained median reductions over 80% over a five-month period November 05, 2022 10:30 AM Eastern Daylight Time LONDON–(BUSINESS WIRE)–Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing […]
Findings presented at AHA Scientific Sessions November 07, 2022 09:00 AM Eastern Standard Time CHICAGO–(BUSINESS WIRE)–The Family Heart Foundation, a leading research and advocacy organization, shared results from an analysis of its large U.S. Family Heart DatabaseTM showing significant disparities exist in the treatment of familial hypercholesterolemia (FH) among racial groups, and […]
Contact: Beth Bales, bbales@vascularsociety.org, (312) 334-2316 Society for Vascular Surgery HEADLINE: For patients with good veins, consider surgery, not endovascular treatment CHICAGO, (Nov. 7, 2022) – For patients at risk for amputation because of severe peripheral artery disease (PAD) – who have a good single segment great saphenous vein […]
